Forward-Looking Statements
This current report contains “forward-looking statements”. All statements, other than statements of historical fact, included herein, including without limitation those regarding Halozyme’s acquisition of Elektrofi and the ability of the parties to consummate the Merger on the proposed terms and contemplated timing are, or may be deemed to be, forward-looking statements. Forward-looking statements are typically, but not always, identified through use of the words “expect,” “believe,” “enable,” “may,” “will,” “could,” “can,” “durable,” “growth,” “innovate,” “develop,” “vision,” “potential,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “possible,” “should,” “continue,” and other words of similar meaning and involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, uncertainties concerning future matters such as market conditions, changes in domestic and foreign business changes in the competitive environment in which Halozyme and Elektrofi operate, and financing a potential transaction, inability of the parties to successfully or timely consummate a transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined group or the expected benefits of a transaction, unexpected levels of the combined group’s revenues, expenditures and costs, unexpected results or delays in the growth of the combined group’s business, or in the development, regulatory review or commercialization of the combined group’s partnered or proprietary products, unexpected early expiration or termination of the patent terms for the combined group’s drug delivery technologies, unexpected levels of revenues (including royalty revenue received from the combined group’s collaboration partners and revenues from proprietary product sales), expenditures and costs, unexpected results or delays in the growth of the combined group’s business (including as a result of unexpected conversion rates) or other proprietary product revenues, or in the development, regulatory review or commercialization of the combined group’s partnered products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on Halozyme’s consolidated financial condition or results of operations. These and other factors that may result in differences are discussed in greater detail in Halozyme’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Except as required by law, Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.
